1. Myers RP, Shah H, Burak KW, et al. An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015;29(1):19–34.
2. European Medicines Agency. Zepatier (elbasvir/grazoprevir) film-coated tablets: EU summary of product characteristics. 2016. http://www.ema.europa.eu/ . Accessed 4 Apr 2017.
3. Merck & Co., Inc. Zepatier™ (elbasvir and grazoprevir) tablets, for oral use: US prescribing information 2016. http://www.merck.com/ . Accessed 4 Apr 2017.
4. Merck & Co., Inc. Merck to present new data on Zepatier™ (elbasvir/grazoprevir) and chronic hepatitis C clinical development programs at The Liver Meeting® [media release]. 3 October 2016. http://www.businesswire.com/ . Accessed 4 Apr 2017.
5. Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Chemmedchem. 2013;8(12):1930–40.